Premium
Market spiral pricing of cancer drugs
Author(s) -
Light Donald W .,
Kantarjian Hagop
Publication year - 2013
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28321
Subject(s) - medicine , cancer drugs , cancer , drug prices , drug pricing , risk analysis (engineering) , actuarial science , public economics , business , economics
High patented cancer drug prices are not related to the high cost of development or to the relative benefit of individual drugs over available ones. Several steps could be implemented to reduce these high prices to more acceptable ones.